ArticleJournal of animal science and biotechnology2025
Limosilactobacillus reuteri SXDT-32-derived shikimic acid protects against colonic inflammation in piglets by inhibiting the PI3K-Akt pathway.
Article in Journal of animal science and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Screening and characterization of Limosilactobacillus reuteri L16 and its probiotic properties in Hy-Line Brown chicks.Poultry science · 2026Article
- Host-Microbiota Interactions in the Regulation of Intestinal Health in Weaned Piglets: Molecular Mechanisms and Nutritional Intervention Strategies.Animals : an open access journal from MDPI · 2026Review
- Early-life intervention withFrontiers in microbiology · 2026Article
- Vitamin K protects against lipopolysaccharide-induced intestinal inflammation in piglets by inhibiting the MAPK and PI3K-AKT pathways.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundColitis caused by bacterial infection is a major global health challenge. Unfortunately, current treatment options are limited. We previously disclosed that L. reuteri SXDT-32 was enriched in the feces of an ancient diarrhea-resistant pig breed (Mashen pig) in China over 2500 years old. As diarrhea is often closely associated with intestinal inflammation, L. reuteri SXDT-32 was identified as a potential beneficial bacterium to prevent intestinal inflammation. However, the precise mechanisms involved remained unclear.
resultsOur tests showed that L. reuteri SXDT-32 alleviated colonic damage induced by pathogenic E. coli SKLAN202302 in weaned pigs by enhancing barrier integrity and inhibiting inflammation. The transcriptomics revealed that L. reuteri SXDT-32 protected against inflammatory injury by inhibiting the PI3K-AKT signaling pathway. Metabolite analysis indicated that the content of shikimic acid (SA) was substantially elevated in the colonic mucosa of L. reuteri SXDT-32-fed piglets (P < 0.05). In addition, Liquid Chromatography-Mass Spectrometer (LC-MS) analysis showed significant increases in SA content in both the colonic chyme of L. reuteri SXDT-32-fed piglets and the supernatant of in vitro grown cultures of L. reuteri SXDT-32 (P < 0.05). Polymerase chain reaction (PCR) analysis identified gene aroE from L. reuteri SXDT-32, which is a key gene directly linked to SA synthesis, and elevated shikimate dehydrogenase (SD, encoded by aroE) was also detected in both L. reuteri SXDT-32 and the colonic mucosa of piglets fed L. reuteri SXDT-32 (P < 0.01). In vitro Caco-2 cell experiments demonstrated that SA, L. reuteri SXDT-32, and the supernatant from in vitro grown cultures of L. reuteri SXDT-32 exhibited comparable inhibitory effects on the PI3K-Akt pathway to those of the PI3K inhibitor LY294002.
conclusionsL. reuteri SXDT-32 alleviated intestinal inflammation in piglets by producing SA that inhibits the PI3K-Akt pathway. This study provides an innovative approach for the treatment and prevention of colitis caused by bacterial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.